Los Angeles Capital Management LLC Acquires 21,501 Shares of Insulet Corporation (NASDAQ:PODD)

Los Angeles Capital Management LLC increased its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 386.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,062 shares of the medical instruments supplier's stock after purchasing an additional 21,501 shares during the quarter. Los Angeles Capital Management LLC's holdings in Insulet were worth $7,107,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Wealth Alliance LLC boosted its position in Insulet by 8.6% during the 1st quarter. Wealth Alliance LLC now owns 1,037 shares of the medical instruments supplier's stock worth $272,000 after acquiring an additional 82 shares during the period. Sargent Investment Group LLC boosted its position in Insulet by 263.9% during the 1st quarter. Sargent Investment Group LLC now owns 3,475 shares of the medical instruments supplier's stock worth $913,000 after acquiring an additional 2,520 shares during the period. IFP Advisors Inc boosted its position in Insulet by 823.4% during the 1st quarter. IFP Advisors Inc now owns 1,265 shares of the medical instruments supplier's stock worth $332,000 after acquiring an additional 1,128 shares during the period. AustralianSuper Pty Ltd acquired a new stake in Insulet during the 1st quarter worth about $9,171,000. Finally, Diversify Advisory Services LLC boosted its position in Insulet by 29.7% during the 1st quarter. Diversify Advisory Services LLC now owns 1,179 shares of the medical instruments supplier's stock worth $296,000 after acquiring an additional 270 shares during the period.

Insiders Place Their Bets

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president directly owned 23,180 shares in the company, valued at $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.39% of the company's stock.

Analyst Upgrades and Downgrades

PODD has been the subject of several research reports. Raymond James Financial reiterated an "outperform" rating and set a $360.00 price target (up from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Wall Street Zen lowered Insulet from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Wells Fargo & Company set a $322.00 price target on Insulet in a report on Monday, April 28th. Truist Financial initiated coverage on Insulet in a report on Monday, June 16th. They set a "buy" rating and a $365.00 price target for the company. Finally, Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a report on Tuesday, May 13th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $321.00.

Insulet Trading Up 1.2%

NASDAQ:PODD traded up $3.43 during mid-day trading on Friday, hitting $290.01. The company had a trading volume of 73,235 shares, compared to its average volume of 770,951. Insulet Corporation has a fifty-two week low of $173.00 and a fifty-two week high of $329.33. The business's fifty day moving average is $306.37 and its two-hundred day moving average is $281.45. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47. The firm has a market cap of $20.41 billion, a P/E ratio of 52.22, a P/E/G ratio of 2.56 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The firm had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. During the same quarter in the prior year, the firm posted $0.73 earnings per share. The company's quarterly revenue was up 28.8% on a year-over-year basis. As a group, research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.